Sanofi & Regeneron Pharmaceuticals announce results for Dupixent study
Dupixent showed significant improvement in patients with acute chronic rhinosinusitis with nasal polyps as well…
Novartis to pursue development of therapy for elevated Lipoprotein(a)
The company would be licensing the rights to develop as well as commercialize TQJ230 for…
Merck agrees to buy Immune Design to enhance immunotherapy portfolio
Merck & Co. has recently announced that it has agreed to acquire Immune Design in…
BioSig Technologies conducts first human PURE EPTM System evaluation
The positive result positions the company well on delivering its strategic goals for 2019 and…
U.S. Food & Drug Administration grants Fast Track Designation to ARS-1
ARS-1 can be used for rapid delivery of epinephrine with less hesitation during an allergic…
Bausch Health acquires rights for preservative-free allergy eye drop
The EM-100 developed by Eton Pharmaceuticals would be the first ever preservative-free eye drop available…
QIAGEN partners with Ares Genetics to strengthen AMR research
QIAGEN can use Ares Genetics’ Antimicrobial Resistance (AMR) database and use its expertise in bioinformatics…
PRODIGY, developed by Medtronic for OIRD yields preliminary results
The study was aimed at developing and internally validating the PRODIGY score, which is an…
Cancer diagnostics firm Burning Rock closes $125.5m Series C funding
The company wants to establish a global leader in tumor precision medicine brand and also…
Innovent Biologics initiates Phase I clinical trial of IBI101
The clinical study is meant to evaluate the primary efficacy, tolerance and safety of IBI101.…